Frontiers in Nutrition (Nov 2022)

Angiotensin-converting enzyme inhibitory peptides and isoflavonoids from soybean [Glycine max (L.) Merr.]

  • Ayyagari Ramlal,
  • Aparna Nautiyal,
  • Pooja Baweja,
  • Vikash Kumar,
  • Sahil Mehta,
  • Rohit Kumar Mahto,
  • Rohit Kumar Mahto,
  • Shikha Tripathi,
  • Shikha Tripathi,
  • Aravindam Shanmugam,
  • Bingi Pujari Mallikarjuna,
  • Pushpa Raman,
  • S. K. Lal,
  • Dhandapani Raju,
  • Ambika Rajendran

DOI
https://doi.org/10.3389/fnut.2022.1068388
Journal volume & issue
Vol. 9

Abstract

Read online

Angiotensin-converting enzyme I (ACE I) is a zinc-containing metallopeptidase involved in the renin-angiotensin system (RAAS) that helps in the regulation of hypertension and maintains fluid balance otherwise, which results in cardiovascular diseases (CVDs). One of the leading reasons of global deaths is due to CVDs. RAAS also plays a central role in maintaining homeostasis of the CV system. The commercial drugs available to treat CVDs possess several fatal side effects. Hence, phytochemicals like peptides having plant-based origin should be explored and utilized as alternative therapies. Soybean is an important leguminous crop that simultaneously possesses medicinal properties. Soybean extracts are used in many drug formulations for treating diabetes and other disorders and ailments. Soy proteins and its edible products such as tofu have shown potential inhibitory activity against ACE. Thus, this review briefly describes various soy proteins and products that can be used to inhibit ACE thereby providing new scope for the identification of potential candidates that can help in the design of safer and natural treatments for CVDs.

Keywords